Two cases of esophageal primary melanoma in females aged 63 and 68 years with nodular and lentiginous forms of growth are reported. The diagnosis was made intraoperatively and at autopsy, respectively. Morphogenetically, there were primary multiple non-simultaneous zones of tumor growth with the apposition growth as a form of tumor progression. Early stages of morphogenesis were characterized by atypical borderline melanocytic activity, melanoma in situ with a starting invasive growth being basic criteria for diagnosis of primary esophageal melanoma in examination of endoscopic and surgical material.
Download full-text PDF |
Source |
|---|
Publication Analysis
Top Keywords
Similar Publications
ZSH-2208: A novel retinoid with potent anti-tumour effects on ESCC stem cells via RARγ-TNFAIP3 axis.
Clin Transl Med
January 2025
Institute of Clinical Science, Zhongshan Hospital, Fudan University Shanghai Medical College, Shanghai, China.
Backgroud: Oesophageal cancer ranks among the most prevalent malignant tumours globally, primarily consisting of oesophageal squamous cell carcinoma (ESCC). Cancer stem cells (CSCs) accelerate the progression ESCC via their strong self-renewal and tumourigenic capabilities, presenting significant clinical challenges due to increased risks of recurrence and drug resistance.
Methods: Our previous study has reported WYC-209, which is capable of inducing apoptosis of CSCs in melanoma and hepatoma, but is ineffective against ESCC.
A Rare and Rapidly Progressive Case of Primary Esophageal Malignant Melanoma in an Elderly Patient.
Cureus
November 2024
Internal Medicine, Unidade Local de Saúde do Alto Minho, Viana do Castelo, PRT.
Primary malignant melanoma of the esophagus (PMME) is a rare malignancy typically associated with poor prognosis, particularly in elderly patients. Here, we present the case of an 85-year-old female patient with a three-month history of progressive dysphagia and heartburn-related epigastric pain. Endoscopy revealed a polypoid esophageal lesion, confirmed as melanoma via biopsy with positive immunohistochemical staining for Melan-A and SOX-10.
View Article and Find Full Text PDFExploring the Pharmacological Mechanisms of P-hydroxylcinnamaldehyde for Treating Gastric Cancer: A Pharmacological Perspective with Experimental Confirmation.
Curr Mol Pharmacol
December 2024
Research Center, The Fourth Hospital of Hebei Medical University, Jiankang Road 12, Shijiazhuang 050011, China.
Background: Momordica cochinchinensis is a dried and mature seed of Cucurbitaceae plants, which has the effect of dispersing nodules, detumescence, attacking poison, and treating sores, and is used in the treatment of tumors in the clinic. P-hydroxylcinnamaldehyde (CMSP) is an ethanol extract of cochinchina momordica seed (CMS). Our previous studies have found that CMSP is an effective anti-tumor component with good anti-tumor effects on melanoma and esophageal tumors.
View Article and Find Full Text PDFComprehensive pan-cancer analysis of CD73: Explore its association with prognosis and tumor immune microenvironment.
Heliyon
November 2024
Department of Clinical Laboratory, The First Affiliated Hospital of Xi'an JiaoTong University, Xi'an, 710061, China.
Article Synopsis
- CD73 is an important molecule involved in immune regulation and its role in the tumor microenvironment was investigated using multiple cancer databases, revealing elevated levels in several cancer types like esophageal carcinoma and glioblastoma.
- The study found that high CD73 expression was often linked to poor overall survival in various cancers such as breast and lung cancers, although in some cases (like kidney and uterine cancers), high expression was associated with better outcomes.
- Additionally, tumors with high CD73 expression showed increased immune scores and positive correlations with immune cell infiltration, indicating a complex relationship between CD73 and the immune response in tumors.
Want AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!